Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Short Candidates -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (684)	6/15/2004 3:32:52 AM
From: tuck	Respond to of 897

Probably a good thing that I closed the AFFX short recently: >>June 14, 2004 BOSTON (CBS.MW) -- Affymetrix (AFFX: news, chart, profile) said Monday evening that it's raising its 2004 net income guidance by 10 cents a share, from 50 cents to 60 cents a share for the year. The genomic toolmaker attributed the change to its recent agreement with rival Oxford Gene Technology to convert their patent licensing agreement into a one-time payout to OGT. Under the agreement, Affymetrix will pay OGT $42 million in licensing fees, plus $20.5 million in royalties over 10 years, for a total payout of $62.5 million. The deal will result in Affymetrix recording a $6 million gain to its net income for the second half of 2004, the company said in a Securities and Exchange Commission filing. Affymetrix closed down $0.01 at $27.18 on Monday. The company added that there will be no additional royalties owed to OGT after the $62.5 million payment is made. Affymetrix also said that it expects to post most of the 10-cent gain in the fourth quarter of 2004. Its guidance for the second quarter this year remains unchanged at 3 cents a share. << I was thinking of buying some for Trickle at these levels, but I may have missed my best entry for a while. Cheers, Tuck

To: mopgcw who wrote (684)	9/13/2004 1:23:51 PM
From: tuck	Respond to of 897

It would appear Meg is one of the more optimistic analysts wrt to sales of Fuzeon. GILD combo now approved, last quarter pretty bad . . . now stock is up over 15% in the last couple of days since announcing a CEO with some commercial experience. Meg said this shouldn't impact the stock. My instinct is to short it right here. Given that they may identify a longer acting formulation soon, I'm going to go with half a position now, and if it pops on a good quarter or on new formulation news, to add the other half then. So: a half position at $14.15. Cheers, Tuck